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Abstract
Background: Coronary artery disease has been linked with genotypes for haptoglobin (Hp) which modulates
extracorpuscular hemoglobin. We hypothesized that the Hp genotype would predict progression of coronary artery
calcification (CAC), a marker of subclinical atherosclerosis.
Methods: CAC was measured three times in six years among 436 subjects with type 1 diabetes and 526 control
subjects participating in the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study. Hp typing was
performed on plasma samples by polyacrylamide gel electrophoresis.
Results: The Hp 2-2 genotype predicted development of significant CAC only in subjects with diabetes who were
free of CAC at baseline (OR: 1.95, 95% CI: 1.07-3.56, p = 0.03), compared to those without the Hp 2-2 genotype,
controlling for age, sex, blood pressure and HDL-cholesterol. Hp 2 appeared to have an allele-dose effect on
development of CAC. Hp genotype did not predict CAC progression in individuals without diabetes.
Conclusions: Hp genotype may aid prediction of accelerated coronary atherosclerosis in subjects with type 1
diabetes.
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Background
Coronary artery disease (CAD) is the leading cause of
death in patients with type 1 diabetes and CAD mortal-
ity is 2-4 higher among type 1 diabetes patients than in
subjects without diabetes [1,2]. While hyperglycemia
and conventional cardiovascular risk factors contribute
to this increased risk, they do not account for all of the
excess risk. Therefore additional markers are needed to
predict which individuals with type 1 diabetes are at
greatest risk for developing CAD [3]. Coronary artery
calcium (CAC) is a powerful marker of the coronary
artery plaque burden [4]. Both the presence and pro-
gression of CAC have been shown to predict CAD
events [5]and mortality [6].
Haptoglobin (Hp) is a protein whose primary function
is to modulate the fate and toxicity of extracorpuscular
hemoglobin [7]. The Hp protein is polymorphic with
two classes of alleles, designated 1 and 2. In most popu-
lations of European ancestry, the prevalence of the Hp
1 - 1g e n o t y p ei s<2 0 % ;H p2 - 1a n dH p2 - 2h a v e
approximately equal frequencies [8]. The protein pro-
ducts of the Hp 1 and Hp 2 alleles are structurally and
functionally distinct. The Hp 1 protein mediates more
rapid clearance of free hemoglobin and provides super-
ior protection against hemoglobin-driven oxidation
compared to the Hp 2 protein [7].
Studies in patients with type 2 diabetes have reported
a 2-5 fold increased risk of myocardial infarction, stroke
or CAD death in patients with the Hp 2-2 genotype,
compared to those without the Hp 2-2 genotype [9-13].
In patients with type 1 diabetes, the Hp 2-2 genotype
conferred an approximately 2-fold increased risk of
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found in Hp 2-1 individuals [9].
The association between the Hp genotype and CAC
has not been previously examined. The purpose of this
study was to investigate the Hp genotype as a predictor
of CAC progression in adults with and without type 1
diabetes. Based on previous prospective studies of CAD,
we hypothesized that the Hp 2-2 genotype would pre-
dict CAC progression in patients with type 1 diabetes,
but not in those without diabetes.
Methods
Study participants
The Coronary Artery Calcification in Type 1 Diabetes
(CACTI) study enrolled 1,416 individuals between 19
and 56 years of age, with no known history of CAD: 652
participants with type 1 diabetes and 764 control partici-
pants without diabetes. Twenty five people were
excluded because they had a coronary event. Of those
remaining, 172 individuals with type 1 diabetes and 216
controls have not completed the 6 year follow-up exam-
ination. Additional subjects were excluded because of
missing plasma sample (n = 28) or inability to determine
the Hp genotype (n = 13), leaving 436 subjects with dia-
betes and 526 controls in the analyses. The baseline
CAD risk factors for the CACTI participants included in
the analyses did not differ from those who were
excluded, except for younger age of excluded controls.
Participants with type 1 diabetes had long-standing dis-
ease (mean duration ± SD: 23 years ± 9 years) at base-
line, were insulin dependent within 1 year of diagnosis,
and were diagnosed prior to age 30 years or had positive
antibodies or a clinical course consistent with type 1
diabetes. All study participants provided informed con-
sent and the study protocol was approved by the Color-
ado Multiple Institutional Review Board.
Coronary Artery Calcium Measurement
At each examination, an ultrafast Imatron C-150XLP
EBCT scanner (Imatron, San Francisco, CA) was used
to obtain two sets of high resolution, noncontrast, con-
tiguous 3-mm tomographic images acquired at 100-ms
exposure. Scanning started from near the lower margin
of bifurcation of the main pulmonary artery with the
subject breathholding for ~35-45 s and proceeded caud-
ally. Calcified coronary artery areas were identified as
those with a minimum density of 130 Hounsfeld units
(HU) and a minimum area of three pixels (1.03 mm2).
A calcium score for each region was calculated by mul-
tiplying the area by the density score (1 for 130-199, 2
for 200-299, 3 for 300-399, and 4 for > 399 HU). A total
CAC score in Agatston units (AU) was calculated by
adding up scores for all slices separately for left main,
left anterior descending, circumflex, and right coronary
arteries [14]. The scanner was recalibrated every day
with a phantom. Effective radiation dose for an EBCT
sequence was 1.0 mSV for men and 1.3 mSV for
women [15].
The presence of any CAC at baseline was defined as a
CAC score > 0 on either of the two scans. CAC progres-
s i o nw a sd e f i n e da sac h a n g ei ns q u a r er o o tC A C
volume ≥ 2.5, as this difference was determined to be <
1% likely to be due to measurement error, based on the
two scans that were completed within 5 minutes of one
another [16]. The same CAC measurement protocol was
followed at the baseline and 6 year follow up visit.
Haptoglobin typing
Hp typing was performed on stored plasma samples by
polyacrylamide gel electrophoresis as previously
described [17]. Briefly, 10 ul of Hb enriched plasma was
subjected to electrophoresis in a non-denaturing gel and
the gel was subsequently immersed in solution contain-
ing a congener of benzidine with a precipitate forming
in the gel corresponding to the location of Hb-Hp com-
plexes. The Hp type of the sample was determined by
the banding pattern of the Hp-Hb complexes with each
of the three Hp types having a characteristic banding
fingerprint. Previous work has established a 1:1 corre-
spondence between this method and a PCR based
method for Hp genotyping [17]. An unambiguous Hp
type was obtained on 98.7% of all samples. For the pur-
poses of quality and control and validation, we simulta-
neously measured the Hp type using an ELISA based
assay [7,18] with a greater than 97% agreement in the
Hp type assigned by the two methods.
Statistical analysis
We used two analytic approaches to examine the asso-
ciation between CAC and Hp polymorphism: linear
regression and logistic regression. For both analyses, we
considered the following baseline CAD risk factors as
covariates: sex, age, diastolic blood pressure (mmHg),
systolic blood pressure (mmHg), body mass index (Kg/
m
2) (BMI), low-density lipoproteins (LDL), high-density
lipoproteins (HDL), triglycerides, hemoglobin A1c (%),
self-reported history of ever smoking, and baseline
square root transform of the CAC volume among those
with CAC present at the baseline examination. We used
backwards selection to build the most parsimonious
model; this selection process entails removing the cov-
ariate that has the largest p-value given the other covari-
ates in the model until all covariates included have a p
v a l u e<0 . 0 5 .A n yc o v a r i a t ew h o s ep - v a l u ew a sn o t<
0.05 in the multivariate model was not included in the
final adjusted model. Assessment of baseline CAD risk
factors have been previously described [15]. The out-
come in linear regression analyses was the change in
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follow up period. For logistic regression analyses, CAC
progression was defined as a change in the square root
transformed CAC volume ≥ 2 . 5o v e rt h e6y e a rp e r i o d
of follow-up, which corresponds to a change in CAC
volume from 0 to ≥ 6.25 among participants initially
free from CAC. This cut off was chosen because it is
the point at which the change in CAC is significant
enough that it can not be attributed to interscan varia-
bility [16]. All analyses were performed using SAS for
Windows version 9.2 (SAS Institute Inc., Cary, NC,
USA).
Results
Table 1 describes the demographic characteristics of the
study population stratified by diabetes status and CAC
progression over a mean time between the baseline and
the follow up visit of 6.5 years (± 0.6, minimum: 4, max-
imum: 9). In the univariate comparison, the frequency of
the Hp 2-2 polymorphism did not differ by CAC pro-
gression (p = 0.13 in participants with type 1 diabetes
and p = 0.17 in those without diabetes).
Linear regression of the change in square root transform
CAC volume
The Hp 2-2 polymorphism predicted change in CAC
volume only in subjects with type 1 diabetes who were
free of CAC at the baseline visit (Table 2, bold type).
The findings were similar with adjustment for age and
sex only (p = 0.03) and when additionally adjusting for
systolic blood pressure and HDL-cholesterol (p = 0.05).
Hp polymorphism was not associated with change in
CAC volume in subjects with type 1 diabetes with CAC
present at baseline or in subjects without diabetes,
regardless of CAC extent at baseline.
Logistic regression of 6 year CAC progression
Similar to the above findings, the Hp 2-2 polymorphism
predicted development of CAC (a change in CAC
volume from 0 to ≥ 6.25 or in square root transformed
CAC volume from 0 to ≥ 2.5) only in subjects with type
1 diabetes free of CAC at theb a s e l i n ee x a m i n a t i o n
when adjusting for age and sex (OR: 2.03, 95% CI: 1.13-
3.65, p = 0.02), and when additionally adjusting for sys-
tolic blood pressure and HDL cholesterol (OR: 1.95,
95% CI: 1.07-3.56, p = 0.03) compared to those without
the Hp 2-2 polymorphism (Table 3). Hp polymorphism
did not predict CAC progression in individuals without
diabetes.
Among patients with diabetes free of CAC at baseline,
Hp 2 appeared to have an allele-dose effect on develop-
ment of CAC: Hp 2-1 OR: 1.72 (1.09-2.71) and Hp 2-2
OR: 2.94 (1.87-4.65), compared to Hp 1-1 and adjusting
for age and sex (Figure 1).
Discussion
The major finding of this study is that the Hp 2-2 poly-
morphism, and to a lesser extent the 2-1 polymorphism,
Table 1 Baseline characteristics in study subjects with 6 year progression data and Hp genotype data by diabetes
status
Characteristic Study subjects with type 1 diabetes Control subjects without type 1 diabetes
6 Year CAC Progression
≥ 2.5
6 Year CAC Progression
< 2.5
6 Year CAC Progression
≥ 2.5
6 Year CAC Progression
< 2.5
n = 178 n = 258 n = 150 n = 376
CAC present at baseline visit 113(63) 37(14) * 86(57) 51(14) *
Haptoglobin genotype 2-2 76(43) 89(35) 46(31) 139(37)
Mean 6 year change in CAC
volume
7.4 ± 4.4 0.4 ± 0.8 * 5.8 ± 3.1 0.3 ± 0.7 *
Female 78(44) 160(62) * 41(27) 223(59) *
Mean age (years) 40.1 ± (8.1) 34.0 ± 8.2) * 45.2 ± 7.3) 39.0 ± 8.5 *
Mean diastolic blood pressure
(mmHg)
78.0 ± 9.0 76.3 ± 8.4 * 83.2 ± 8.9 77.2 ± 7.6 *
Mean systolic blood pressure
(mmHg)
120.2 ± 13.6 113.9 ± 12.1 * 120.4 ± 12.7 111.6 ± 11.1 *
Mean body mass index (kg/m
2) 26.7 ± 4.3 25.6 ± 4.0 * 28.2 ± 4.8 25.3 ± 4.4 *
Mean LDL cholesterol (mmol/l) 2.7 ± 0.73 2.5 ± 0.7 * 3.1 ± 0.8 3.0 ± 0.8 *
Mean HDL cholesterol (mmol/l) 1.4 ± 0.4 1.5 ± 0.4 * 1.2 ± 0.3 1.4 ± 0.4 *
Mean triglycerides (mmol/l) 1.1 ± 0.01 1.0 ± 0.5 * 1.8 ± 1.2 1.3 ± 0.7 *
Mean HbA1c (%) 8.0 ± 1.2 7.8 ± 1.2 5.6 ± 0.4 5.4 ± 0.4 *
Ever smoker 48(27) 39(15) * 27(18) 86(23)
* p-value less than 0.05 comparing CAC progression in individuals with type 1 diabetes and control subjects separately
Data are presented as mean ± sd or as n (%)
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people with type 1 diabetes over a period of 6 years.
The findings were internally consistent, using two defi-
nitions of CAC progression in linear and logistic regres-
sion analyses. Our finding that Hp polymorphisms
predict new CAC only in patients with diabetes is con-
sistent with previous reports from studies using clinical
CAD endpoints [9,10,12,13].
Consistent with our findings, the Pittsburgh Epide-
miology of Diabetes Complications Study of patients
with type 1 diabetes, has shown an allele-dose effect of
the Hp 2 allele on the risk of incident CAD [9]. Thus,
among individuals with type 1 diabetes, the Hp 2 allele
plays an important role in subclinical coronary athero-
sclerosis and progression to clinical events.
The apparent lack of effect of Hp genotype on pro-
gression of CAC in patients already CAC positive is
puzzling and requires further evaluation. While we
adjusted for baseline extent of CAC in the models
among patients already CAC positive, it is possible that
Table 2 Adjusted b estimates from linear regression analyzing the association between Hp genotype and square root
transformed CAC volume, stratified by the presence of CAC at baseline
Adjusting for age
and sex only
Including
covariates from
backwards
selection model*
Characteristic b
estimate
p-value b
estimate
p-value
Hp genotype * diabetes interaction*presence of CAC at
baseline interaction
N/A 0.001 N/A 0.001
CAC not present at the baseline visit Hp 2-2 vs. 2-1/1-1 in patients with
diabetes
0.82 0.03 0.74 0.05
Hp 2-2 vs. 2-1/1-1 in controls without
diabetes
0.67 0.2 0.83 0.11
CAC present at the baseline visit Hp 2-2 vs. 2-1/1-1 in patients with
diabetes
-0.34 0.3 -0.31 0.33
Hp 2-2 vs. 2-1/1-1 in controls without
diabetes
-2.02 0.52 0.24 0.7
Age 0.11 < 0.0001 0.1 < 0.0001
Female vs. male -1.17 < 0.0001 0.22 0.001
Systolic blood pressure N/A 0.01 < 0.0001
HDL cholesterol N/A 0.01 0.003
* Adjusting for age, sex, systolic blood pressure and HDL-cholesterol
Table 3 Adjusted odds ratios for the association between CAC progression and Hp genotype, stratified by presence of
CAC at baseline
Adjusting for age and
sex only
Including covariates
from backwards
selection model*
Characteristic OR 95% CI p-value OR 95% CI p-value
Hp genotype * diabetes interaction*presence of CAC at
baseline interaction
N/A 0.03 N/A 0.09
CAC not present at the baseline visit Hp 2-2 vs. 2-1/1-1 in patients with
diabetes
2.03 1.13-3.65 0.02 1.95 1.07-3.56 0.03
Hp 2-2 vs. 2-1/1-1 in controls
without diabetes
0.83 0.37-1.84 0.65 0.69 0.38-1.27 0.94
CAC present at the baseline visit Hp 2-2 vs. 2-1/1-1 in patients with
diabetes
0.68 0.37-1.24 0.21 0.80 0.33-1.93 0.22
Hp 2-2 vs. 2-1/1-1 in controls
without diabetes
1.33 0.94-3.28 0.07 1.17 0.49-2.81 0.29
Age 1.08 1.05-1.10 < 0.0001 1.08 1.05-1.10 0.009
Female vs. male 0.43 0.31-0.60 < 0.0001 0.65 0.45-0.94 < 0.0001
Systolic blood pressure N/A 1.03 1.02-1.05 < 0.0001
HDL cholesterol N/A 0.97 0.96-0.99 0.0001
Square root CAC volume at baseline N/A 1.25 1.13-1.38 < 0.0001
* Adjusting for age, sex, systolic blood pressure and HDL-cholesterol
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remains. In addition, incident CAC and CAC progres-
sion may reflect different biological processes and prog-
noses. The development of CAC is a process which
increases risk for future acute coronary events, [5] and
CAC progression is a powerful predictor of mortality
even among persons who already have CAC present; [6]
However, calcification of a plaque itself does not pro-
mote plaque rupture [19].
No other cohorts with data about incident CAC in
individuals with type 1 diabetes exist in which to vali-
date our findings. However, the results of this study vali-
date those from studies of clinical endpoints by using
the subclinical outcome of CAC, thereby demonstrating
that the Hp genotype is a robust biomarker for athero-
sclerosis in individuals with type 1 diabetes.
The different effect of Hp 1 and Hp 2 proteins on car-
diovascular risk in patients with diabetes potentially
derives from several mechanisms. First, Hp regulates the
fate and toxicity of extracorpuscular hemoglobin [7].
Upon binding to hemoglobin, the Hp 1 protein is super-
ior to the Hp 2 protein in protecting against oxidation
mediated by Hb derived iron [20] and HDL dysfunction,
[21] particularly in the setting of diabetes. In addition,
recent evidence suggests a more diverse physiologic role
for Hp. Delanghe et al. summarized the evidence that
Hp polymorphisms play a role in the regulation of both
T- and B- cells, particularly with respect to the immune
response to atherosclerosis and Hb driven lipid oxida-
tion [22]. Other recent publications presented data sug-
gesting that Hp (both genotype and circulating
concentrations) has a role in remodeling the myocar-
dium and, therefore, prognosis after myocardial infarc-
tion (MI) [23,24]. To help elucidate these mechanisms,
future observational research may want to study the
association between Hp concentration and CAC devel-
opment as well as the interaction between the immuno-
logic profile of people with type 1 diabetes and Hp.
Conclusions
This study adds to the literature concerning the
increased risk for CAD among patients with type 1 dia-
betes who have the Hp 2 allele and extends that
research by studying progression of subclinical athero-
sclerosis rather than clinical CAD events. In so doing,
this study has identified a sub-group of people towards
whom primary prevention efforts may be directed. For
example, the ICARE study found that vitamin E is useful
in prevention of clinical cardiovascular events among
individuals with type 2 diabetes and the Hp 2-2 poly-
morphism [25,26]. Therefore, it may be useful to initiate
a similar clinical trial targeted at Hp 2-2 individuals
with type 1 diabetes and no CAC. Furthermore, utiliza-
tion of incident CAC, as opposed to hard clinical events,
Figure 1 Plot of age and sex-adjusted odds ratios (OR) for incident CAC by the number of Hp 2 alleles, stratified by type 1 diabetes.
Simpson et al. Cardiovascular Diabetology 2011, 10:99
http://www.cardiab.com/content/10/1/99
Page 5 of 7would allow for a markedly less costly trial design asses-
sing the efficacy of such a pharmacogenomic algorithm.
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